Limitations include small cohorts, short follow-up, heterogeneous peptide types and doses, and mixed endpoints
On June 6, Pfizer published detailed Phase 2b data for berobenatide (PF3944), positioning it as a potential first-in-class once-monthly GLP-1 receptor agonist peptideand laid out a wide Phase 3 plan for 2026
Evidence Supporting Exercise and Protein Intake There are currently no clinical trials specifically examining protein intake during GLP-1 treatment, but higher protein intake combined with resistance training is beneficial: A 2025 case series published in SAGE Open Medicine described three patients using semaglutide or tirzepatide who engaged in resistance training 3 to 5 days weekly and consumed protein at 0.36 to 0.77 g/lb of total body weight (0.73 to 1.04 g/lb of fat-free mass)
In agreement with this, a novel sKlotho assay (IP-IB) was shown to display better performance than other available sKlotho assays, which may resolve this issue in the future (Neyra et al., 2020b)
A Holiday to Remember With these GLP-1-friendly mocktails, you can enjoy the spirit of the holiday season while keeping your health goals in mind
